Shattuck Labs, Inc. (STTK)
| Market Cap | 2.05B |
| Revenue (ttm) | 10.76M |
| Net Income (ttm) | -27.41M |
| Shares Out | 39.84M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $49.64 |
| Previous Close | $50.00 |
| Change ($) | -0.36 |
| Change (%) | -0.72% |
| Day's Open | 50.05 |
| Day's Range | 47.14 - 51.34 |
| Day's Volume | 75,255 |
| 52-Week Range | 19.00 - 57.61 |
AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
AUSTIN, TX and DURHAM, NC, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
AUSTIN, TX and DURHAM, NC, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
– Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer –
AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional f...
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...
DURHAM, N.C. and AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-funct...
DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...
U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week
Shares of Shattuck Labs Inc. soared in their public debut, as they opened 30% above the initial public offering price. The stock's first trade was at $22.10 at 11:10 a.m.
Shattuck Labs Inc. said its initial public offering, which was upsized by about 19%, priced above the expected range at $17 a share, as the Texas-based biotechnology company focused on cancer ...
DURHAM, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new cla...
About STTK
Shattuck Labs, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
| Industry Research and Development in Biotechnology | IPO Date Oct 9, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol STTK |
Financial Performance
In 2019, Shattuck Labs's revenue was $9.89 million, a decrease of -55.94% compared to the previous year's $22.44 million. Losses were -$23.98 million, 224.6% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Shattuck Labs stock is "Strong Buy." The 12-month stock price forecast is 54.50, which is an increase of 9.79% from the latest price.